|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300079291 |
|
最近更新日期: Date of Last Refreshed on: |
2023-12-29 11:12:30 |
|
注册时间: Date of Registration: |
2023-12-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
三臂整群随机对照试验评估精准优化的“接力种”干预策略对15-18岁女性HPV疫苗接种率提升的效果 |
|
Public title: |
Assessment of the effect of precision-optimized Pay-it-forward Intervention strategy on improving HPV vaccination rates among females aged 15-18: A three-arm clustered randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
三臂整群随机对照试验评估精准优化的“接力种”干预策略对15-18岁女性HPV疫苗接种率提升的效果 |
|
Scientific title: |
Assessment of the effect of precision-optimized Pay-it-forward Intervention strategy on improving HPV vaccination rates among females aged 15-18: A three-arm clustered randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陆娅胶 |
研究负责人: |
李静 |
|
Applicant: |
Lu Yajiao |
Study leader: |
Li Jing |
|
申请注册联系人电话: Applicant telephone: |
+86 178 6062 5638 |
研究负责人电话:
Study leader's |
+86 132 4022 5540 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
3021560893@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
lijingwcph@scu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区人民南路三段17号 |
研究负责人通讯地址: |
四川省成都市武侯区人民南路三段17号 |
|
Applicant address: |
17 Renmin Road South, Wuhou District, Chengdu, China |
Study leader's address: |
17 Renmin Road South, Wuhou District, Chengdu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学 |
||
|
Applicant's institution: |
Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西公共卫生学院 |
||
|
Affiliation of the Leader: |
West China School of Public Health, Sichuan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
Gwll2023229 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西第四医院/华西公共卫生学院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of West China Fourth Hospital and West China School of Public Health, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-11-07 00:00:00 | ||
|
伦理委员会联系人: |
刘丹萍 |
||
|
Contact Name of the ethic committee: |
Liu Danping |
||
|
伦理委员会联系地址: |
四川省成都市武侯区人民南路三段16号 |
||
|
Contact Address of the ethic committee: |
16 Renmin Road South, Wuhou District, Chengdu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8550 8845 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
hxgwsylunli@163.com |
|
研究实施负责(组长)单位: |
四川大学华西公共卫生学院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
West China School of Public Health, Sichuan University |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区人民南路三段17号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
17 Renmin Road South, Wuhou District, Chengdu, China |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
比尔及梅琳达·盖茨基金会 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Bill & Melinda Gates Foundation |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
宫颈癌 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Cervical cancer |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
(1)比较不同干预组之间的疫苗接种率 (2)比较分析不同干预对于研究对象疫苗信心和延迟疫苗接种的影响 (3)分析不同干预措施的成本效果 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
(1) Compare the vaccination rates among different intervention groups. (2) Analyze and compare the impact of different interventions on vaccine confidence and delayed vaccine uptake among the study subjects. (3) Analyze the cost-effectiveness of different intervention measures |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
(1)15-18 岁青少年女性;(2)无HPV疫苗接种史;(3)既往无严重 、危及生命的疫苗过敏症(4)法定监护人同意参加该研究的 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria are females: 1) aged 15–18years; 2) with no HPV vaccination history, 3) with no prior allergies to vaccines; and 4) have a legal guardian who consents to participate the study. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.小于15或大于18的女性;2.已接种过HPV疫苗;3. 根据医生的临床评估,无法接种疫苗的人;4.法定监护人拒绝参与该研究。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria are females: 1) aged below 15 or above 18years;2) received HPV vaccine(s); 3) ineligible to receive a vaccine based on clinical evaluation from a physician; or 4) a legal guardian refuses to consent to participate. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-11-01 00:00:00至 To 2025-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-01-01 00:00:00 至 To 2025-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究助理(RA)通过计算机软件SPSS 21.0生成与分组相匹配的随机数字序列,并通过与序列相匹配学校ID号进行随机分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The research assistant (RA) utilized computer software SPSS 21.0 to generate randomly matched numerical sequences for grouping. The randomization was performed by matching school ID numbers with the generated sequences. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
与项目结果一同上传公开(开源发表)至某国际期刊 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
We will publish the data files along with the study findings (open access) to an international journal. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic data capture system will be uesd. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |